Fostemsavir plus optimized background therapy was associated with improvements in immune biomarkers among HTE patients with MDR HIV infection.

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

a drug used to treat type 2 diabetes, could help deplete the viral reservoir and eliminate it entirely in people living with HIV who receive antiretroviral ... Potential Link Between DNA Markers ...

As the nation's AIDS walk marks its 40th year in Los Angeles, organizers say medical advances have taken lowered visibility ...

The increased prevalence of substance use disorder among people living with HIV during the COVID-19 pandemic may be attributable ... was used to evaluate substance use among participants. For each ...

Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is a brand-name tablet prescribed for HIV-1. As with other drugs, Biktarvy can cause side effects, such as ...

The number of templates might be less than other products, but 156 is more than enough and it has all the critical ones like Network diagrams, organizational charts and floor plans. The feature ...

Too much of anything can be bad, and the consequence of too much of drugs is something we are all familiar with. Not all of us have tried these drugs, but cinema has shown us the most graphic and ...

Biktarvy is a complete treatment for HIV. This means you take the medication by itself, without other antiretroviral drugs (drugs used to treat HIV). If you have trouble swallowing tablets ...

When highly active antiretroviral therapy (HAART) was first introduced in 1996, the average life expectancy of a 20-year-old newly infected with HIV was 10 years from the time of diagnosis. This new ...

Data were sourced from 19 observational cohorts and more than 30,000 people with HIV in Europe and Australia. Adults on dual or triple combination antiretroviral therapy who had CD4, HIV RNA, and at ...

Faster access to HIV drug lenacapavir in India hinges on the waiver of local clinical trials. Six companies, including three from India, have non-exclusive, royalty-free licenses to produce generic ...